Hepatology

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.

The decision to revoke the conditional marketing authorization is based on a June 2024 CHMP recommendation from the EMA suggesting the benefits of Ocaliva do not outweigh its risks.

A study suggests transient elastography and fibrosis-4 index may be effective in predicting hepatocellular carcinoma risk in hepatitis C patients.

Data for more than 2 million blood donors in Canada provides insight into HCV antibody positivity trends in this notoriously low-risk patient population.

The restrictive strategy led to fewer cholecystectomies without increasing complications but did not improve pain-free outcomes versus usual care for symptomatic cholelithiasis.

Endoscopic ultrasound-guided rendezvous technique and precut sphincterotomy had similar technical success, and failure with one method could be successfully cannulated with the other.

A study found that women with trauma history have reduced liver transplant access compared to men, with gender disparities not driven by psychiatric symptoms.

A new study found hepatitis C virus reinfections may occur within 24 weeks of sustained virologic response after injecting drugs.

Patients who underwent ERCP ≤ 30 days post-transplant had greater rates of early post-procedure bleeding but similar rates of technical and clinical success compared to late ERCP.

Findings support the use of liver grafts from donation after circulatory death and HCV-positive donors, citing comparable 1-year patient and graft survival.

Kumar explains what is known about the use of PPAR agonists in primary biliary cholangitis and the significance of the recent FDA accelerated approvals of elafibranor and seladelpar.

The third quarterly issue of 2024 reviews early versus late ERCP outcomes post-transplant, the impact of GLP-1RA use on endoscopic management, and the differential diagnosis of seronegative villous atrophy.

Findings suggest the benefit of early HCV detection and treatment with DAAs for improving liver-related outcomes and reducing fibrotic burden.

Stretching and meditation both reduced cramp severity and improved sleep quality with no significant differences. However, patients preferred stretching.

Estimates based on NHANES data suggest 15.6 million US adults have used a potentially hepatotoxic botanical herbal and dietary supplement product within the past 30 days.

Results suggest paternal hepatitis B virus infection prior to pregnancy is associated with a 40% increased risk of congenital heart diseases in their children.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

Moderate alcohol consumption did not significantly impact liver-related parameters in patients with the Pi*MZ and Pi*ZZ genotypes of alpha-1 antitrypsin deficiency.

In this video segment, Reau, Trivedi, and Hirschfield discuss the EMA opinion on obeticholic acid and its impact on discussions about second-line therapies amid the influx of new treatment options available for patients.

In this video segment, Reau, Trivedi, and Hirschfield discuss the availability of new second-line treatment options and their role in PBC management compared to traditional therapies like UDCA and OCA.

In this video segment, Reau, Trivedi, and Hirschfield discuss recent shifts in treatment goals for patients with PBC and a new focus on timely intervention with second-line options.

A new study found physical activity held more weight in the link between the joint exposure of sleep duration, metabolic equivalent of task, and Healthy Eating Index -2015 and MAFLD.

High-risk alcohol use was linked to greater rates of cirrhosis in patients with HCV but did not significantly impact rates of sustained virologic response.

Investigators highlight the need for tailored interventions to improve sleep disturbances and overall health in patients with hepatocellular carcinoma.

The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).

Noureddin explains the discordance between FIB-4 and transient elastography for stratifying fibrosis risk and emphasizes the importance of repetition and attentiveness with FIB-4.

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

Alkhouri explains the value of AGILE 3+ and AGILE 4, reviewing key findings from a recent study applying the scores to NHANES data to estimate MASLD fibrosis and cirrhosis.

Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals.